Vivani Medical Announces Successful Dosing in Phase 1 SLIM-1 Trial

What Happened Vivani Medical, Inc. (NASDAQ: VANI) announced on August 6, 2026 that it has successfully dosed all participants in SLIM‑1, a Phase 1 clinical trial evaluating NPM‑139, a miniature, ultra long‑acting semaglutide implant for chronic weight management. The announcement was made via a press release that the company filed as Exhibit 99.1 to its Form 8‑K (Item 7.01 Regulation FD Disclosure).

Key Details

• Press release dated August 6, 2026; filed as Exhibit 99.1 to the Form 8‑K.
• Trial: SLIM‑1 — a Phase 1 study of NPM‑139, described as a miniature, ultra long‑acting semaglutide implant for chronic weight management.
• Company reports that all participants in the SLIM‑1 study have been dosed (no participant count provided in the filing).
• Disclosure made under Item 7.01 (Regulation FD Disclosure) on Form 8‑K.

Why It Matters Completion of dosing is a clear clinical milestone: it moves the SLIM‑1 program from enrollment/dosing into the data‑collection and follow‑up phases, which may lead to upcoming safety, tolerability or pharmacokinetic readouts. For investors, this reduces near‑term operational uncertainty around enrollment and is a step toward potential future clinical updates that could affect the company’s development timeline and valuation. Investors should watch for subsequent press releases or SEC filings with trial results and next‑step plans.